Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment - a Real-World Prospective Analysis from the Revive Study Group

Blood (2022) 140 (Supplement 1): 9002–9004.

https://doi.org/10.1182/blood-2022-162140

Published: 2022

Journal Articles

Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice - a Prospective Analysis from the Revive Study

Blood (2022) 140 (Supplement 1): 6162–6164.

https://doi.org/10.1182/blood-2022-163020

Published: 2022

Journal Articles

Real World Prospective Observational Multicenter Trial of Venetoclax-Based Therapy for Patients with AML Reveals Unique Patterns of Patient Selection and Treatment Utilization - Revive Study

Ofir Wolach, Itai Levi, David Lavie, Jonathan Canaani, Sigal Tavor, Ilana Hellmann, Tamar Tadmor, Tsila Zuckerman, Galia Stemer, Jenia Berelovich, Keren Ofek, Neta Frankel, Moshe Grunspan, Yishai Ofran, Yakir Moshe

Blood (2021) 138 (Supplement 1): 1246.

https://doi.org/10.1182/blood-2021-147245

Published: 2021

Journal Articles

First Results from a Nationwide Prospective Non-Interventional Study of Venetoclax-Based 1 st Line Therapies in Patients with Acute Myeloid Leukemia (AML) - Revive Study

Ofir Wolach, MD, Itai Levi, MD, Jonathan Canaani, MD, Tamar Tadmor, MD, Sigal Tavor, MD, Ilana Hellmann, MD, Tsila Zuckerman, MD, David Lavie, MD, Galia Stemer, MD, Raanan Cohen, MD, Ran Afik, PhD, Keren Ofek, PhD, Hilla Banayan, BSc MBA, Inna Kan, PhD, Moshe Grunspan, PhD, Yishai Ofran, MD, Yakir Moshe, MD PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-139923

Published: 2020

Journal Articles

Dasatinib Inhibits FLT3 /ITD and PTPN11 mutated Acute Myeloid Leukemia Cells Overexpressing SRC Tyrosine Kinases

Sigal Tavor, MD, Tali Shalit, PhD, Noa Chapal Ilani, PhD, Yoni Moskovitz, PhD, Nir Livnat, BSc, Yoram Groner, PhD, Haim Bar, PhD, Alexander Plotnikov, PhD, Nathali Kaushansky, PhD, Liran I. Shlush, MD

Blood (2019) 134 (Supplement_1): 1451.

https://doi.org/10.1182/blood-2019-128016

Published: 2019

Journal Articles

The ability to cross the blood–cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts

Blood (2016) 127 (16): 1998–2006.

https://doi.org/10.1182/blood-2015-08-665034

Published: 2016

Includes: Supplemental data

Journal Articles

Ruxolitinib Treatment for Myelofibrosis: Efficacy and Tolerability in a Real-World Setting

Martin H. Ellis, MD, Noa Lavi, MD, Elena Mishchenko, MD, Najib Dally, MD, David Lavie, MD, Anna Courevitch, MD, Odit Gutwein, MD, Shlomo Bulvik, MD, Andrei Braester, MD, Evgeni Chubar, MD, Sigal Tavor, MD, Adrian Duek, MD, Ilya Kirgner, MD, Maya Koren-Michowitz, MD

Blood (2014) 124 (21): 1830.

https://doi.org/10.1182/blood.V124.21.1830.1830

Published: 2014

Journal Articles

The CXCR4 Antagonist BL-8040 Efficiently Induces Apoptosis and Inhibits The Survival Of AML Cells

Sigal Tavor, MD, Ido Weiss, Katia Beider, Ph.D., Hanna Wald, Orly Eizenberg, Yaron Pereg, Leah Klapper, Arnon Nagler, MD, MSc, Amnon Peled, Michal Abraham, PhD

Blood (2013) 122 (21): 3939.

https://doi.org/10.1182/blood.V122.21.3939.3939

Published: 2013

Journal Articles

Loss Of H3K27 Trimethylation (H3K27me3) Associates With a Multi Drug Resistance Phenotype In Acute Myeloid Leukemia (AML)

Stefanie Göllner, PhD, Tino Schenk, PhD, Sven Stengel, PhD, Christian Rohde, PhD, Tim Sauer, MD, Arthur Zelent, PhD, Sigal Tavor, MD, Friedrich Stölzel, MD, Gerhard Ehninger, MD, Gabriele Köhler, MD, Wolfgang E. Berdel, MD, Christian Thiede, MD, Carsten Müller-Tidow, MD

Blood (2013) 122 (21): 1253.

https://doi.org/10.1182/blood.V122.21.1253.1253

Published: 2013

Journal Articles

The Predictive Value of TP53 FISH Analysis for Treatment Response and Survival in Cytogenetic Subgroups of AML Patients.

Sigal Tavor, MD, Rachel Rothman, PhD, Tamar Golan, PhD, Nadia Voskoboinik, PhD, Ruth Shomrat, PhD, Avi Orr-Urtreger, MD, PhD, Elizabeth Naparstek, MD

Blood (2009) 114 (22): 2617.

https://doi.org/10.1182/blood.V114.22.2617.2617

Published: 2009

Journal Articles

The CXCR4 Antagonist AMD3100 Impairs Survival of AML Cells and Induces Their Differentiation.

Sigal Tavor, MD, Manny Eisenbach, Jasmine Jacob-Hirsch, Tammar Golan, PhD, Isabelle Petit, PhD, Katz Ben-Zion, PhD, Sigi Kay, PhD, Shoshana Baron, Ninette Amariglio, PhD, Varda Deutsch, PhD, Elizabeth Naparstek, MD, Gideon Rechavi, MD, PhD

Blood (2008) 112 (11): 1621.

https://doi.org/10.1182/blood.V112.11.1621.1621

Published: 2008

Journal Articles

Inhibition of Elastase or SDF-1/CXCR4 Axis Promotes Differentiation of Human AML Cells.

Sigal Tavor, MD, Jasmine Jacob-Hirsch, MSc, Manny Eisenbach, MSc, Sigi Kay, PhD, Shoshana Baron, Ninette Amariglio, PhD, Elizabeth Naparstek, MD, Gideon Rechavi, MD, PhD

Blood (2006) 108 (11): 1891.

https://doi.org/10.1182/blood.V108.11.1891.1891

Published: 2006

Journal Articles

Functional CXCR4 Expressing Microparticles and SDF-1 Correlate with Circulating AML Cell Counts.

Alexander Kalinkovich, MD, PhD, Sigal Tavor, MD, Abraham Avigdor, MD, Joy Kahn, PhD, Alexander Brill, PhD, Isabelle Petit, PhD, Polina Goichberg, PhD, Melania Tesio, M.Sc, Neta Netzer, Ms, Elizabeth Naparstek, Izhar Hardan, MD, Arnon Nagler, Igor Resnick, MD, Alexander Tsimanis, PhD, Tsvee Lapidot

Blood (2006) 108 (11): 4375.

https://doi.org/10.1182/blood.V108.11.4375.4375

Published: 2006

Journal Articles

Motility, proliferation, and egress to the circulation of human AML cells are elastase dependent in NOD/SCID chimeric mice

Sigal Tavor, Isabelle Petit, Svetlana Porozov, Polina Goichberg, Abraham Avigdor, Sari Sagiv, Arnon Nagler, Elizabeth Naparstek, Tsvee Lapidot

Blood (2005) 106 (6): 2120–2127.

https://doi.org/10.1182/blood-2004-12-4969

Published: 2005

Journal Articles

Motility, Proliferation and Egress of Human AML Cells in Transplanted NOD/SCID Mice Are Regulated by Membrane Bound and Secreted Elastase.

Sigal Tavor, MD, Isabelle Petit, PhD, Svetlana Porozov, PhD, Polina Goichberg, PhD, Avraham Avigdor, MD, Sari Sagiv, MSc, Arnon Nagler, MD, Elizabeth Naparstek, MD, Tsvee Lapidot, PhD

Blood (2004) 104 (11): 3379.

https://doi.org/10.1182/blood.V104.11.3379.3379

Published: 2004

Journal Articles

Macrophage functional maturation and cytokine production are impaired in C/EBPε-deficient mice

Sigal Tavor, Peter T. Vuong, Dorothy J. Park, Adrian F. Gombart, Arthur H. Cohen, H. Phillip Koeffler

Blood (2002) 99 (5): 1794–1801.

https://doi.org/10.1182/blood.V99.5.1794

Published: 2002

NARROW

Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment - a Real-World Prospective Analysis from the Revive Study Group

Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice - a Prospective Analysis from the Revive Study

Real World Prospective Observational Multicenter Trial of Venetoclax-Based Therapy for Patients with AML Reveals Unique Patterns of Patient Selection and Treatment Utilization - Revive Study

First Results from a Nationwide Prospective Non-Interventional Study of Venetoclax-Based 1 st Line Therapies in Patients with Acute Myeloid Leukemia (AML) - Revive Study

Dasatinib Inhibits FLT3 /ITD and PTPN11 mutated Acute Myeloid Leukemia Cells Overexpressing SRC Tyrosine Kinases

The ability to cross the blood–cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts

Ruxolitinib Treatment for Myelofibrosis: Efficacy and Tolerability in a Real-World Setting

The CXCR4 Antagonist BL-8040 Efficiently Induces Apoptosis and Inhibits The Survival Of AML Cells

Loss Of H3K27 Trimethylation (H3K27me3) Associates With a Multi Drug Resistance Phenotype In Acute Myeloid Leukemia (AML)

The Predictive Value of TP53 FISH Analysis for Treatment Response and Survival in Cytogenetic Subgroups of AML Patients.

The CXCR4 Antagonist AMD3100 Impairs Survival of AML Cells and Induces Their Differentiation.

Inhibition of Elastase or SDF-1/CXCR4 Axis Promotes Differentiation of Human AML Cells.

Functional CXCR4 Expressing Microparticles and SDF-1 Correlate with Circulating AML Cell Counts.

Motility, proliferation, and egress to the circulation of human AML cells are elastase dependent in NOD/SCID chimeric mice

Motility, Proliferation and Egress of Human AML Cells in Transplanted NOD/SCID Mice Are Regulated by Membrane Bound and Secreted Elastase.

Macrophage functional maturation and cytokine production are impaired in C/EBPε-deficient mice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only